News

Boehringer in HCV partnership
Enlarge image

BusinessGermany

Boehringer in HCV partnership

14.03.2013 - Boehringer Ingelheim and US firm Presidio Pharmaceuticals will combine their drugs against Hepatitis C.

The firms said they entered a non-exclusive collaboration for a 12-week Phase IIa trial of an oral combination treatment for patients with chronic hepatitis C virus (HCV) infection starting in Q2/2013. San Francisco-based Presidio will contribute its second-generation NS5A inhibitor PPI-668 whilst Boehringer Ingelheim will chip in its HCV protease inhibitor faldaprevir (BI201335) and its non-nucleoside HCV polymerase inhibitor BI207127. The combination will be tested with or without ribavirin.

"The study will assess the potential of this three-drug oral regimen to achieve high rates of sustained viral clearance in hepatitis C patients, with good tolerance.", said Dr Nathaniel Brown, DMO of Presidio, who will have primary responsibility for the trial. Both companies will retain all rights to their compounds. Data from the trials are anticipated in Q4/2013.

The current standard treatment for patients with hepatitis C genotype-1 infection is pegylated interferon-alfa (ribavirin) and an HCV protease inhibitor.

© eurobiotechnews.eu/tg

http://www.european-biotechnology-news.com/news/news/2013-01/boehringer-in-hcv-partnership.html

PoliticsFranceUKSweden

24.04.2015 AstraZeneca has boosted its oncology portfolio by signing a US$1.275bn agreement with Innate Pharma. The companies plan to further the development of Innate’s tumour-targeting antibody.

PoliticsEU

22.04.2015 A legislative proposal by the European Commission is set to renationalise market authorisation of genetically modified crops.

FinancingUK

21.04.2015 Ahead of its listing on the London Stock Exchange, Woodford’s Patient Capital Trust has raised a record sum of €1.1bn. The fund met with immense interest by investors.

Swiss Biotech DaySwitzerland

16.04.2015 The Swiss biotech industry can look back on 2014 as a good year, but political uncertainties do remain. This was one of the topics discussed during the Swiss Biotech Day in Basel, which attracted more than 400 participants.

EventEUFrance

16.04.2015 The changing landscape in healthcare was just one of the hotly discussed topics of the 27th Annual EuroMeeting of the international association DIA.

R&DBelgium

14.04.2015 Belgian Thrombogenics NV has launched a new oncology company with Gent-based life sciences institute VIB. The new venture will develop an antibody for the treatment of a fast-growing brain tumour that affects children and adolescents.

Stock MarketsEUFranceUKNorwaySweden

09.04.2015 The European public markets remain highly attractive for biotech companies. Twice as many companies went public in the first quarter of 2015 than during the same period last year.

FinancingAustriaUKSwitzerlandGermany

08.04.2015 To bring its lead product of a new class of antimicrobials to phase 3 trials, Nabriva Therapeutics has completed a US$120m Series B financing.

Research & DevelopmentNetherlands

07.04.2015 Gene therapy is attracting more and more big pharma companies. Now, Bristol-Myers Squibb has forged a US$1bn collaboration with Dutch uniQure, also picking up a 4.9% share in the company.

Stock MarketsFrance

02.04.2015 Sensorion is the latest French biotech to go public, following a spate of IPOs on Paris Euronext. The biopharma plans for a €12m IPO to finance its pipeline of inner ear disease drugs.

Events

All Events

Partner-Events

München

BioVaria 2015

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • WILEX3.59 EUR5.59%
  • BASILEA118.10 CHF3.14%
  • PAION2.58 EUR2.79%

FLOP

  • BIOTEST79.20 EUR-19.51%
  • CYTOS1.01 CHF-8.18%
  • FORMYCON28.00 EUR-6.01%

TOP

  • 4SC1.30 EUR54.8%
  • WILEX3.59 EUR22.9%
  • CO.DON3.15 EUR19.3%

FLOP

  • MOLOGEN5.08 EUR-35.6%
  • CYTOS1.01 CHF-34.4%
  • BIOTEST79.20 EUR-22.5%

TOP

  • SANTHERA98.85 CHF2460.9%
  • CYTOS1.01 CHF676.9%
  • WILEX3.59 EUR337.8%

FLOP

  • MOLOGEN5.08 EUR-54.7%
  • THERAMETRICS0.07 CHF-30.0%
  • BIOFRONTERA2.41 EUR-28.1%

No liability assumed, Date: 24.04.2015